Menu
Washingtoner
  • Home
  • Business
  • Books
  • Health
  • Family
  • Entertainment
  • Technology
  • Apparel
  • Education
Washingtoner

Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
Washingtoner/10175938

Trending...
  • Sonata Software is proud to partner with Microsoft for the launch of Microsoft Fabric
  • 65 Arts, Culture, Heritage, and Science Organizations Funded by Tacoma Creates for 2023-2024
  • IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. ("Kubota Vision"), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride ("emixustat") in patients with macular atrophy secondary to Stargardt disease.

The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 clinical study in which subjects were randomly assigned to emixustat 10 mg or placebo (2:1 ratio) once daily for 24 months. The target total number of subjects was 162; however, due to high interest in the study, a total of 194 subjects were enrolled in this study across 29 sites in 11 countries worldwide. The last patient has completed the study. The primary objective of this study is to determine if emixustat reduces the rate of macular atrophy progression, in comparison to placebo, in subjects with Stargardt disease. Secondary objectives include assessing changes in visual function parameters such as BCVA (best-corrected visual acuity) letter score and reading speed. The database of this study will be locked in the third quarter 2022.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, "Despite Stargardt being a rare disease, we were able to enroll more patients than originally planned and feel grateful that the patients trusted our drug with great expectation and continued taking the drug for two years during the pandemic. We would like to sincerely thank all of the participants and their families for their cooperation and are very pleased that the long-term, large-scale clinical trial has been successfully completed. We are also looking forward to receiving the results of the trial in the coming months."

The FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) granted orphan drug designation to emixustat for the treatment of Stargardt disease. (See January 5, 2017 press release titled "Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease" and June 9, 2019 press release titled "Acucela Receives Orphan Designation from the EMA for Emixustat for the Treatment of Stargardt Disease")

More on Washingtoner
  • Studeo dévoile StudAI : l'Intelligence Artificielle au service de l'éducation
  • EMH Productions Announce 'Live for Liberty' Charity Concert in Los Angeles Supporting "Woman, Life, Freedom" Movement in Iran
  • Spokane: Indian Trail House Fire
  • Spokane: Camp Hope to Close on or Before June 30
  • NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology

About Stargardt Disease

Stargardt disease is a rare, genetically inherited disease that directly affects the retina of the eye, often resulting in the slow progression of vision loss in children. It may also be referred to as Stargardt macular dystrophy or juvenile macular degeneration and affects approximately 1 in 8,000 - 10,000 individuals worldwide.*1 The most common form of the disease is caused by a genetic mutation of the ABCA4 gene leading to the accumulation of toxic vitamin A byproducts (primarily A2E) in the retina, which results in the gradual deterioration of photoreceptors and vision. Symptoms of Stargardt disease typically appear during childhood or adolescence, but in some cases difficulty with eyesight and vision loss may not be identified until later in life.

Stargardt disease affects less than 150,000 patients in total in the U.S., Europe and Japan where it is recognized as an orphan disease. Currently, there are no known therapies that slow the advance of the disease, and it is recognized as a serious unmet medical need.

*1 Facts About Stargardt Disease, National Eye Institute. https://nei.nih.gov/health/stargardt/star_facts, accessed on 14 September 2018.

About Emixustat Hydrochloride

Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process. Slowing the visual cycle reduces the availability of vitamin A derivatives (11-cis- and all-trans-retinal) to form precursors of toxic A2E and related compounds. In addition, reducing the availability of 11-cis-retinal decreases retinal metabolic demands under dark conditions. Emixustat when delivered orally was found to be generally well tolerated in human clinical studies with delayed dark adaptation being the most common adverse event. Kubota Vision is exploring emixustat's potential to stop or slow the progression of vision loss in patients diagnosed with Stargardt disease in an ongoing clinical study.

More on Washingtoner
  • Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
  • Spokane: SPD Seeking Assistance Locating Missing Vulnerable Juvenile
  • Spokane: SPD Seeking Public's Assistance In Locating Shooting Suspect
  • HuskyVPN: The Ultimate Solution for Secure and Private Internet Access
  • Spokane: Flags To Fly at Half-Staff on Memorial Day

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements: https://www.kubotaholdings.co.jp/en/1/index.html

"Kubota Vision", the Kubota Vision logo and "Kubota" are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Contacts

Media and Investor Relations Contact:

Mikio Fukai
Corporate Planning Division
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Council Members Wilkerson and Zappone Partner with State Officials to Secure $1.4 Million for Spokane Police Academy
  • 130k+ Patients' Social Security Numbers Leaked in UHS of Delaware Data Breach
  • Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
  • Tacoma: McKinley Spring Work Party Celebration Happening June 10
  • Ohio Pacing Stallion Catch The Fire Is Heading To Australia
  • IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree
  • Autel Robotics Wins Prestigious Red Dot Design Award 2023 for EVO Max 4T Drone
  • Launch of New Industrial Capabilities and Services Website for Argo Products in St. Louis, Missouri
  • SafeBreak® Vascular Cleared for Pediatrics
  • CartoVista unveils CartoVista Cloud 8.1, the latest in GIS web mapping platforms, at 2023 FCM Conference in Toronto
  • CartoVista unveils CartoVista Cloud at the 2023 FCM Conference in Toronto
  • Sonata Software is proud to partner with Microsoft for the launch of Microsoft Fabric
  • Tacoma: Road Work Restricts Inside Northbound Lane of Pacific Avenue June 1 - 2
  • Seattle School Bus Drivers at Zūm Vote to Authorize a Strike
  • Resurgence Wellness Unveils Revolutionary Anti-Aging Breakthroughs by Tech Pioneer Bryan Johnson
  • Search By Inseam Launches New Website
  • Tacoma: Community Vitality and Safety Committee to Receive Briefing Regarding Proposed Updates to Rental Housing Code on May 25
  • Baked by Michela Announces Grand Opening of Bucks County, Pennsylvania Bakery
  • Senco Home Services Rebuilds Tewksbury Baseball Fields
  • G. Entertainment Proudly Presents The Hip-hop 50th Anniversary Concert
_catLbl0 _catLbl1

Popular on Washingtoner

  • MAG Auctions Announces Premier Collector Car Auction in Salem, Oregon May 19-20, 2023
  • The World's No.1 Superstar is back with a new single and an epic alien-themed music video for "Frustrated."
  • EA Co-Founder Jeff Burton Joins P2Earn Inc As New Advisory Board Chairman
  • Tokyo SKYTREE TOWN® Launches Disney100-Themed Events
  • Prime time celebs discovering the value of social access
  • CW Petroleum Corp (CWPE) Reports Fiscal Year Ended 2022
  • Levitt Pavilion Los Angeles celebrates it's 'sweet sixteen'
  • Spokane: Flags at Half-Staff Honoring the Allen, Texas Shooting Victims
  • City of Tacoma Urges Residents to Prepare for Heat Over the Next Several Days
  • AACE Releases 2023 Type 2 Diabetes Management Algorithm to Support Clinical Decision Making

Similar on Washingtoner

  • ZoomInfo Delivers Product Enhancements Powered by Generative AI and Automation
  • Registration is Now Open for the 2023 CGI Integrated Care Conference
  • Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
  • Levinger-Regens Analytics Reveals New Energy Outlook
  • Redfin Reports Mortgage Rates Surge Past 7.1% For First Time Since November; Some Buyers Back Off While Others Lower Budget
  • Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
  • CartoVista unveils CartoVista Cloud 8.1, the latest in GIS web mapping platforms, at 2023 FCM Conference in Toronto
  • Sonata Software is proud to partner with Microsoft for the launch of Microsoft Fabric
  • Seattle School Bus Drivers at Zūm Vote to Authorize a Strike
  • Baked by Michela Announces Grand Opening of Bucks County, Pennsylvania Bakery
Copyright © 2023 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute